Management of SARS-CoV-2 pneumonia

J Med Virol. 2021 Mar;93(3):1276-1287. doi: 10.1002/jmv.26470. Epub 2020 Oct 10.

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has rapidly spread throughout the world since December 2019 to become a global public health emergency for the elevated deaths and hospitalizations in Intensive Care Units. The severity spectrum of SARS-CoV-2 pneumonia ranges from mild to severe clinical conditions. The clinical course of SARS-CoV-2 disease is correlated with multiple factors including host characteristics (genetics, immune status, age, and general health), viral load and, above all, the host distribution of the airways and lungs of the viral receptor cells. In this review, we will briefly summarize the current knowledge of the characteristics and management of coronavirus disease 2019-pneumonia. However, other studies are needed to better understand the pathogenetic mechanisms induced by SARS-Cov-2 infection, and to evaluate the long-term consequences of the virus on the lungs.

Keywords: COVID-19; SARS-CoV-2; clinical presentation; pneumonia.

Publication types

  • Review

MeSH terms

  • Acute Lung Injury / drug therapy
  • Acute Lung Injury / pathology
  • Acute Lung Injury / physiopathology
  • Anti-Inflammatory Agents / therapeutic use*
  • Antiviral Agents / therapeutic use*
  • COVID-19 / pathology
  • COVID-19 / physiopathology
  • COVID-19 Drug Treatment*
  • Disease Management
  • Humans
  • Lung / diagnostic imaging
  • Lung / pathology
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / pathology
  • Pneumonia, Viral / physiopathology

Substances

  • Anti-Inflammatory Agents
  • Antiviral Agents

Grants and funding